ANERGEN INC
SC 13G, 1996-02-05
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: SMITH BARNEY WORLD FUNDS INC, 497, 1996-02-05
Next: PHYSICIAN SUPPORT SYSTEMS INC, S-1/A, 1996-02-05




                         UNITED STATES                   OMB APPROVAL
              SECURITIES AND EXCHANGE COMMISSION   OMB Number:  3235-0145
                      Washington, D.C. 20549       Expires:   October 31, 1994
                                                   Estimated average burden
                                                   hours per response ... 14.90


                               SCHEDULE 13G



               Under the Securities Exchange Act of 1934

                             (Amendment No. 2)



                               ANERGEN, INC.
- -------------------------------------------------------------------------------
                            (Name of Issuer)


                       Common Stock, no par value
- -------------------------------------------------------------------------------
                      (Title of Class of Securities)


                              034602-10-2
          -------------------------------------------------
                            (CUSIP Number)




Check the following box if a fee is being paid with this statement |_|. (A fee
is not required only if the reporting  person:  (1) has a previous  statement on
file  reporting  beneficial  ownership of more than five percent of the class of
securities  described  in Item 1;  and (2) has  filed  no  amendment  subsequent
thereto reporting  beneficial  ownership of five percent or less of such class.)
(See Rule 13d-7.)





                         Page 1 of 8 pages
<PAGE>


  3100                                              Schedule 13G
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
CUSIP No. 034602-10-2         13G       Page   2    of    8   Pages
          -----------                        ------    -------
- -------------------------------------------------------------------------------
1    NAME OF REPORTING PERSONS
     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
     ORTELIUS TRADING L.P.;    13-3512778
- -------------------------------------------------------------------------------
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (a) |_|
                                                        (b) |_|
- -------------------------------------------------------------------------------
3    SEC USE ONLY
- -------------------------------------------------------------------------------
4    CITIZENSHIP OR PLACE OF ORGANIZATION
       Deleware
- -------------------------------------------------------------------------------
 NUMBER OF     5    SOLE VOTING POWER  0
  SHARES       ----------------------------------------------------------------
BENEFICIALLY   6    SHARED VOTING POWER  0  
 OWNED BY      ----------------------------------------------------------------
  EACH         7    SOLE DISPOSITIVE POWER  0
 REPORTING     ----------------------------------------------------------------
PERSON WITH    8    SHARED DISPOSITIVE POWER 0
- -------------------------------------------------------------------------------
9    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
     PERSON   0    shares of Common Stock
- -------------------------------------------------------------------------------
10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
     CERTAIN SHARES*
- -------------------------------------------------------------------------------
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
      0
- -------------------------------------------------------------------------------
12   TYPE OF REPORTING PERSON
      BD
- -------------------------------------------------------------------------------
                     *SEE INSTRUCTIONS BEFORE FILLING OUT!

<PAGE>
 3100                                              Schedule 13G
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
CUSIP No. 034602-10-2         13G       Page   3    of    8   Pages
          -----------                        -------   -------
- -------------------------------------------------------------------------------
1    NAME OF REPORTING PERSONS
     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
     GDK, Inc.
- -------------------------------------------------------------------------------
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (a)   |_|
                                                        (B)   |_|
- -------------------------------------------------------------------------------
3    SEC USE ONLY
- -------------------------------------------------------------------------------
4    CITIZENSHIP OR PLACE OF ORGANIZATION
       British Virgin Islands
- -------------------------------------------------------------------------------
   NUMBER OF      5 SOLE VOTING POWER  340,371
    SHARES        -------------------------------------------------------------
  BENEFICIALLY    6 SHARED VOTING POWER 0
   OWNED BY       -------------------------------------------------------------
     EACH         7 SOLE DISPOSITIVE POWER  340,371
   REPORTING      -------------------------------------------------------------
  PERSON WITH     8 SHARED DISPOSITIVE POWER 0
- -------------------------------------------------------------------------------
9    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
     PERSON   340,371 shares of Common Stock
- -------------------------------------------------------------------------------
10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
     CERTAIN SHARES*
- -------------------------------------------------------------------------------
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
       2.3%
- -------------------------------------------------------------------------------
12   TYPE OF REPORTING PERSON
       BD
- -------------------------------------------------------------------------------
                      *SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
Item 1(a).     Name of Issuer:

  Anergen, Inc.


Item 1(b).     Address of Issuer's Principal Executive Offices:

  301 Penobscot Drive
  Redwood City, California 94063


Item 2(a).     Name of Person Filing:

  This  Amendment 2 to Form 13G is being filed by (i) GDK,  Inc., a  corporation
formed under the laws of the British  Virgin  Islands  ("GDK"),  with respect to
shares of common stock of the issuer ("Common Stock")  beneficially  owned by it
as of December 31, 1995,  and (ii)  Ortelius  Trading  L.P., a Delaware  limited
partnership ("Ortelius").

  As of December 31, 1995,  Ortelius no longer  beneficialy  owned any shares of
Common Stock.

  Pursuant to Rule  13d-3(d)(1),  the aggregate number of shares of Common Stock
beneficially  owned by GDK as of December  31, 1995,  is 340,371.  This total is
comprised of 223,217  shares of Common Stock and 117,154  shares of Common Stock
underlying a warrant which is  exercisable  at the discretion of GDK at any time
between now and June 30,  1997.  GDK also has entered  into a so-called  "equity
swap" with respect to 135,000  shares of Common Stock.  Pursuant to the contract
which effects the equity swap, GDK (i) receives a fixed return of 1.5% per annum
on the value of the contract and, on a quarterly  basis,  an amount equal to any
decrease  in the value of the  135,000  shares of Common  Stock below an initial
base price of $3.625 per share, as adjusted on  pre-determined  valuation dates,
and (ii) is  obligated  to pay, on a  quarterly  basis,  an amount  equal to any
increase  in the value of the  135,000  shares of Common  Stock above an initial
base price of $3.625 per share, as adjusted on  pre-determined  valuation dates.
The contract does not affect GDK's right to vote and/or dispose of the shares of
Common Stock owned by it. Caxton Corporation, a Delaware corporation ("Caxton"),
is GDK's trading advisor. Subject to termination of its contractual relationship
with GDK by a vote of its Board of  Directors,  Caxton  acts on behalf of GDK as
its  trading  advisor.  In  such  capacity,   Caxton  directs  GDK's  securities
investments  and is vested with authority over the voting and disposition of the
shares of Common Stock.


                         Page 4 of 8 pages
<PAGE>

Item 2(b).     Address of Principal Business Office, or, if None,
Residence.

  The address of the principal office of Ortelius Trading L.P. is
667 Madison Avenue, 10th floor, New York, New York 10021.  The
address of the principal office of GDK, Inc. is c/o its Manager,
Leeds Management Limited, 129 Front Street, Penthouse, Hamilton
HM12 Bermuda.


Item 2(c).     Citizenship:

  Ortelius:  Delaware
  GDK:       British Virgin Islands


Item 2(d).     Title of Class of Securities:

  Common Stock, no par value


Item 2(e).     CUSIP NUMBER:  034602-10-2


Item 3. The reporting  persons  originally  filed as a group, in accordance with
Rule  13d-1(b)(1)(ii)(H).  Each of the  reporting  persons is a broker or dealer
registered under Section 15 of the Securities  Exchange Act of 1934.  Subsequent
to the disposition of the Common Stock beneficially owned by Ortelius,  Ortelius
filed Form BDW in order to withdraw its broker-dealer registration.


Item 4.   Ownership.

  (a) Amount beneficially owned: The amount of securities  beneficially owned by
Ortelius as of December 31, 1995, is zero. The amount of securities beneficially
owned by GDK as of December 31, 1995, is 340,371,  consisting,  pursuant to Rule
13d-3(d)(1),  of  223,217  shares  of  Common  Stock  and  a  warrant  currently
exercisable for 117,154 shares of Common Stock.

  (b) Percent of class:  As of December 31, 1995,  Ortelius  beneficially  owned
0.0% of the class of Common  Stock.  As of December 31, 1995,  GDK  beneficially
owned 2.3% of the class of Common Stock.

  (c)  Number of shares as to which Ortelius has:
       (i) Sole power to vote or to direct the vote:  0
       (ii) Shared power to vote or to direct the vote: 0
       (iii) Sole power to dispose or to direct the disposition
of: 0

                         Page 5 of 8 pages
<PAGE>
       (iv) Shared power to dispose or to direct the disposition
of:  0

       Number of shares as to which GDK has:
       (i) Sole power to vote or to direct the vote:  340,371
       (ii) Shared power to vote or to direct the vote:  0
       (iii) Sole power to dispose or to direct the disposition
of:  340,371
       (iv) Shared power to dispose or to direct the disposition
of:  0


Item 5.  Ownership of Five Percent or Less of a Class.  Each of Ortelius and GDK
has ceased to be the  beneficial  owner of more than five  percent of the Common
Stock.


Item 6.   Ownership of More than Five Percent on Behalf of
Another Person.  NA


Item 7.   Identification and Classification of the Subsidiary
Which Acquired the Security Reported on the Parent Holding
Company.  NA


Item 8.   Identification and Classification of members of the
Group.  NA


Item 9.   Notice of Dissolution of Group.  NA


Item 10.  Certification.

  By signing below,  each of the reporting persons hereby certifies that, to the
best of its knowledge and belief, the securities referred to above were acquired
in the ordinary  course of business and were not acquired for the purpose of and
do not have the effect of changing or  influencing  the control of the issuer of
such  securities and were not acquired in connection with or as a participant in
any transaction having such purpose or effect.


                         Page 6 of 8 pages
<PAGE>
                            SIGNATURE

Afterreasonable inquiry and to the best of the undersigned's knowledge and
belief, the undersigned certifies that the information set forth in this
statement is true, complete, and correct.

February , 1996
- ------------------
Date

GDK, INC.



  By:__________________________
     Maxwell Quin
     Secretary



  By:__________________________
     Nitin Aggarwal
     President




                         Page 7 of 8 pages
<PAGE>

                            SIGNATURE

  After reasonable  inquiry and to the best of the  undersigned's  knowledge and
belief,  the  undersigned  certifies  that  the  information  set  forth in this
statement is true, complete, and correct.



February    , 1996
- --------------------
Date

ORTELIUS TRADING L.P.

  By:  Caxton Corporation



  By:_____________________________
     Peter D'Angelo
     President


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission